Online inquiry

IVTScrip™ mRNA-Anti-PDGFRB, REGN-2176(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13891MR)

This product GTTS-WQ13891MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets PDGFRB gene. The antibody can be applied in Age-related macular degeneration (AMD) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002609.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5159
UniProt ID P09619
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDGFRB, REGN-2176(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13891MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15606MR IVTScrip™ mRNA-Anti-SLC29A2, VAL-1221(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA VAL-1221
GTTS-WQ7320MR IVTScrip™ mRNA-Anti-FGFR2, FPA-144(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA FPA-144
GTTS-WQ6379MR IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CSL654
GTTS-WQ4107MR IVTScrip™ mRNA-Anti-oxLDL, BI-204(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BI-204
GTTS-WQ6424MR IVTScrip™ mRNA-Anti-HA, CT-P22(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CT-P22
GTTS-WQ3725MR IVTScrip™ mRNA-Anti-MSLN, BAY 94-9343(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BAY 94-9343
GTTS-WQ8206MR IVTScrip™ mRNA-Anti-SLC39A6, hLIV22(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA hLIV22
GTTS-WQ15701MR IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA VEGF Trap
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW